LONDON, May 1, 2015 /PRNewswire/ --
A new report by visiongain forecasts the overall world market for antithrombotic drugs will reach $22.4bn in 2019. That revenue forecast and others appear in Antithrombotic Drugs: World Industry and Market Prospects 2015-2025, published in March 2015.
The purpose of that investigation is to provide forecasts and qualitative analyses of the antithrombotic drugs market. Visiongain is a business information publisher and consultancy in London, UK. It produces analyses to help organisations understand potentials of industries and markets.
That new study analyses the antithrombotic drugs market in 2013 and 2014, as well as forecasting its prospects for revenue growth from 2015 to 2025. In particular, the work examines 14 leading products on the market in 2014, providing revenue forecasts for each as well as the overarching market and its segments.
Visiongain predicts the antithrombotic drugs market will recover from the sharp decline following patent expiries for Plavix and Lovenox in 2012. Although the market may not reach the same heights as it did in 2011 when Plavix revenue totalled $9.6bn, the patient population for antithrombotic drugs expands. The study finds the market will expand following its prior decline, until it faces patent expiries for other leading drugs in the second half of the forecasted period.
Alyscia Curtis, a pharmaceutical industry analyst in visiongain, said: "The world market for antithrombotic drugs generated $20.2bn in 2014. Although the loss of patent protection for Plavix and Lovenox has severely impacted the market, there is still potential for growth in the 2015-2025 period. The industry is changing, and novel anticoagulants are becoming the market leaders. The warfarin replacement market is large and with several compounds now vying for position. As antidotes become available for these novel anticoagulants, the market will grow. However, in the latter half of the forecast period, the antithrombotics market will decline as a result of patent expiries, generic competition and a limited pipeline. However, with a growing number of people suffering from cardiovascular diseases, and with aging populations, the antithrombotic drugs market retains promise for developments and revenue generation."
Visiongain's updated analysis shows revenue forecasts to 2025 at overall world market, submarket, product (brand) and national level. First it gives revenue predictions to 2025 for therapeutic submarkets at world level:
- Anticoagulants, also with sub-forecasts for direct factor Xa inhibitors, heparins, direct thrombin inhibitors and vitamin K antagonists
- Antiplatelet agents
That study then predicts revenues of 14 leading drugs to 2025. Medicines forecasted and discussed include Plavix, Lovenox, Xarelto, Pradaxa, Activase, Effient, Aspirin Cardio and Pletal.
Research, data and analyses cover activities of Sanofi, Boehringer Ingelheim, Bayer, Johnson & Johnson, Genentech, The Medicines Company, Eli Lilly, Pfizer and other developers, manufacturers and marketers of antithrombotic drugs.
That new study also discusses R&D and commercial news, shows two research interviews and predicts revenues to 2025 in 11 leading national markets. The work analyses the United States (US), Western Europe (Italy, Spain, Germany, the UK and France), Japan and BRIC countries (Brazil, Russia, India and China).
Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 adds to visiongain's analyses on industries and markets in healthcare. Together those studies cover pharmaceuticals, diagnostics, medical devices, outsourced services and biotechnologies.
For sample pages, and for further information about this report please visit https://www.visiongain.com/Report/1417/Antithrombotic-Drugs-World-Industry-and-Market-Prospects-2015-2025
For an executive summary please contact:
Email: Sara Peerun on firstname.lastname@example.org
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44(0)207-336-6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first portofcall for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.
Companies Listed In This Company
Asahi Kasei Pharma America
Barr Laboratories (subsidiary of Barr Pharmaceuticals)
Barr Pharmaceuticals (now a part of Teva Pharmaceuticals)
Baylor College of Medicine, Houston, Texas
Capital TEN II
Committee on Medicinal Products for Human Use (CHMP)
Dr. Reddy's Laboratories
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
German Institute for Quality and Efficiency in Health Care (IQWiG)
Hercules Bioventures Partners
Hoechst Marion Roussell
Johns Hopkins Medicine
Johnson & Johnson (J&J)
Judicial Panel on Multidistrict Litigation (US)
Kyowa Hakko Kirin
LG Life Sciences
Merck & Co.
Mitsubishi Tanabe Pharma
National Health Service (NHS)
National Institute for Health and Care Excellence (NICE)
Otsuka Pharmaceutical Company
Pharmaceutical and Medical Devices Agency (PMDA)
Sun Pharmaceuticals Indusdtries
Teva Pharmaceutical Industries
The Medicines Company
Tufts Medical Center
Unified Health System (SUS)
Universidade Federal de São Paulo
University General Hospital
University of Insubria (Italy)
US Department of Justice
Virginia Commonwealth University
World Health Organization (WHO)
Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York
Zydus Pharmaceuticals (USA) Inc. (US Division of Cadila Healthcare)
To see a report overview please email Sara Peerun on firstname.lastname@example.org